Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the top long-term biotechnology stocks to buy. On October 27, SELLAS Life Sciences (NASDAQ:SLS) announced the immediate exercise of warrants for ...
SELLAS Life Sciences Group (SLS) is back on traders’ radar after fresh data from its leukemia program, including strong response rates and supportive FDA designations, helped spark a sharp move in the ...
NEW YORK, May 26, 2021 /PRNewswire/ -- Bruderman Brothers, LLC ("Bruderman Brothers"), is pleased to announce the successful sale of HealthEx Corporation ("HealthEx") to Associated Courier, Inc. ("ACI ...
15d
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement
SELLAS Life Sciences Group (SLS) has entered an agreement with IMPACT-AML, a pan-European clinical network, to run a new study of its CDK9 inhibitor SLS009 in high-risk newly diagnosed acute myeloid ...
The average one-year price target for SELLAS Life Sciences Group (NASDAQ:SLS) has been revised to 7.14 / share. This is an increase of 16.67% from the prior estimate of 6.12 dated October 31, 2023.
Fintel reports that on September 7, 2023, Cantor Fitzgerald reiterated coverage of SELLAS Life Sciences Group (NASDAQ:SLS) with a Overweight recommendation. As of August 31, 2023, the average one-year ...
SELLAS Life Sciences Group Inc. Times Square Tower 7 Times Square Suite 2503 New York, New York 10026 Phone1 646 200-5278 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2024 ...
Good morning, and welcome to the SELLAS Life Sciences R&D Day. As a reminder, this call is being recorded, and a replay will be made available on the SELLAS website following the conclusion of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results